Pfizer (IRSH)

Pfizer (IRSH)

Blog posts

Thoughts on AstraZeneca

Shareholders in AstraZeneca are no doubt pleasantly surprised by the uplift in the share price following the offers from Pfizer. The share price has doubled in the last year on improving prospects with an even sharper increase in the last few weeks as soon as a bid was rumoured. That puts the company on a historic p/e of about 20 at the time of writing. AstraZeneca has of course been a dog for some years with falling revenue and earnings, a poor ...